CADTH conducted a Health Technology Review looking for evidence on the clinical effectiveness of sotrovimab, a human monoclonal antibody, for the treatment of COVID-19. No published, peer-reviewed evidence was identified. However, 1 trial that is currently under way has preliminary results. Final results are expected later this year and should provide further clarity on the potential role of sotrovimab for the treatment of individuals with COVID-19.

Link to Report

CADTH Health Technology Review: Sotrovimab for the Treatment of COVID-19

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.